Company: CMND
Filing Date: 2025-12-05
Form Type: 6-K
Source: 0001213900-25-118712
Chunk: 0

Company: Clearmind Medicine Inc.
Filing Date: 2025-12-05
Form: 6-K
Chunk 0
---
<div align='center'>UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

For the month of: December 2025

Commission file number: 001-41557

CLEARMIND MEDICINE INC.

(Translation of registrant’s name into English)

101 – 1220 West 6th Avenue

Vancouver, British Columbia

(Address of principal executive offices)</div>

Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.

<div align='center'>Form 20-F ☒
Form 40-F ☐

CONTENTS</div>

As previously disclosed, on
November 3, 2025, Clearmind Medicine Inc. (the “Company”) received a written notification from the Listing Qualifications
Department of Nasdaq Stock Market LLC (“Nasdaq”), notifying the Company that it is no longer in compliance with Nasdaq Listing
Rule 5550(b)(1) (the “Minimum Stockholders’ Equity Rule”), which requires companies listed on the Nasdaq Capital Market
to maintain a minimum of $2,500,000 in stockholders’ equity for continued listing.

On September 17, 2025, the
Company entered into securities purchase agreements with investors to which the Company shall issue and sell, from time to time, convertible
promissory notes (the “Promissory Notes”) in the aggregate principal amount of up to $10,000,000. As of the date hereof, the
Company has issued Promissory Notes in the aggregate principal amount of $2.5 million, of which an aggregate of $2.2 million of outstanding
amounts due under the Promissory Notes were converted into 4,135,000 of the Company’s common shares. In addition, in November 2025
and as of December 3, 2025, the Company raised approximately $7.25 million in gross proceeds from registered direct offerings of common
shares and pre-funded warrants, and as of December 3, 2025, the Company has issued 2,090,987 common shares as a result of the exercises
for cash and on a cashless basis of warrants to purchase 2,894,